vaccin
effect
method
diseas
prevent
control
mani
virus
bacteria
caus
catastroph
pandem
eg
smallpox
poliomyel
measl
diphtheria
either
erad
effect
control
routin
vaccin
program
nonetheless
vaccin
manufactur
remain
incred
challeng
virus
exhibit
high
antigen
divers
high
mutat
rate
fairli
contest
use
tradit
vaccin
product
method
complex
surround
manufactur
process
impos
signific
limit
viruslik
particl
vlp
recombinantli
produc
viral
structur
exhibit
immunoprotect
trait
nativ
virus
noninfecti
sever
vlp
composit
match
given
natur
viru
develop
licens
vaccin
expans
plethora
studi
confirm
vlp
design
safe
present
heterolog
antigen
varieti
pathogen
unrel
chosen
carrier
vlp
owe
design
versatil
vlp
offer
technolog
opportun
modern
vaccin
suppli
diseas
respons
ration
bioengin
opportun
greatli
enhanc
applic
synthet
biolog
redesign
construct
novel
biolog
entiti
review
outlin
synthet
biolog
current
appli
engin
vlp
function
manufactur
process
current
develop
technolog
identif
novel
targetspecif
antigen
use
ration
engin
vlp
function
eg
present
structur
divers
antigen
enhanc
antigen
immunogen
improv
vaccin
stabil
describ
appli
manufactur
process
synthet
biolog
approach
also
overcom
specif
challeng
vlp
vaccin
product
final
address
sever
challeng
benefit
associ
translat
vlp
vaccin
develop
industri
k
e
w
r
abil
integr
biolog
data
comput
analysi
synthet
biolog
significantli
contribut
move
vaccin
develop
beyond
constraint
pasteur
assist
design
novel
biolog
system
enhanc
efficaci
safeti
well
reduc
vaccin
product
time
ruder
lu
collin
today
focu
gear
toward
use
vlp
vaccin
unmodifi
viral
assembl
parent
virus
also
scaffold
display
heterolog
antigen
et
al
synthet
biolog
becom
centerpiec
vlp
vaccin
engin
second
multitud
tool
omic
technolog
structur
biolog
system
immunolog
bioinformat
comput
biolog
one
screen
pathogenspecif
antigen
high
immunogen
potenti
appli
inform
ration
design
modern
vlp
vaccin
figur
influenza
one
best
exampl
omic
precis
genom
revolution
vaccin
design
dedic
databas
detail
complet
accur
influenza
genom
inform
creat
readili
access
worldwid
mchardi
adam
last
decad
vast
wealth
data
translat
knowledg
conjunct
synthet
biolog
aid
design
vlp
vaccin
candid
prabakaran
et
al
pushko
et
al
pushko
et
al
novel
biolog
entiti
undoubtedli
safer
potenti
broadli
reactiv
previou
counterpart
ie
tradit
commerci
avail
live
attenu
influenza
vaccin
sever
genom
applic
aid
identif
novel
antigen
liao
et
al
name
revers
vaccinolog
compar
function
genom
revers
vaccinolog
combin
genom
proteom
bioinformat
identifi
virtual
potenti
protect
antigen
code
region
within
genom
bambini
rappuoli
rappuoli
compar
genom
primarili
use
design
broadli
protect
vaccin
allow
comparison
conserv
variabl
open
read
frame
within
speci
function
genom
allow
identif
protein
function
base
revers
genet
evalu
mutat
knockout
gene
express
analysi
transcriptom
bagnoli
et
al
bambini
rappuoli
rappuoli
sett
rappuoli
although
genom
per
se
contribut
significantli
design
mani
vaccin
candid
influenza
prabakaran
et
al
pushko
et
al
pushko
et
al
malaria
draper
et
al
wu
narum
fleuri
jen
yadava
human
immunodefici
viru
hiv
calazan
boggiano
lindsay
full
potenti
vaccin
develop
realiz
integr
proteom
immunom
bagnoli
et
al
moreov
coordin
deploy
omic
technolog
along
miniatur
bioprocess
screen
exampl
microbioreactor
microfluid
cell
cultur
system
aid
develop
assess
lead
acceler
manufactur
bhambur
kumar
rathor
gong
lei
hemmerich
noack
wiechert
oldig
immunom
specif
address
interfac
host
immun
system
pathogen
proteom
studi
subset
pathogenderiv
protein
epitop
recogn
host
immun
system
inform
use
valid
antigen
identifi
silico
andor
vitro
approach
evalu
whether
target
clinic
relev
immun
respons
ie
stimul
product
specif
cytokin
activ
specif
cell
type
et
al
exampl
immunom
applic
vlp
vaccin
design
glaxosmithklin
rt
vaccin
advanc
malaria
vaccin
candid
rt
chimer
vlp
larg
portion
ctermin
plasmodium
falciparumderiv
circumsporozoit
protein
csp
display
protein
scaffold
hepat
b
surfac
antigen
wu
et
al
combin
system
biolog
genom
proteom
immunom
use
highlight
region
within
csp
immunogen
protect
human
thu
indispens
incorpor
chimer
vlp
mani
candid
identifi
one
prove
success
phase
iiab
efficaci
trial
draper
et
al
kazmin
et
al
structur
inform
use
reconfigur
engin
conserv
epitop
expos
area
exhibit
high
immunogen
insert
multipl
immunodomin
epitop
within
vlp
platform
liljeroo
malito
ferlenghi
bottomley
strategi
broaden
immun
respons
enhanc
exist
respons
weak
immunogen
antigen
identifi
conform
epitop
studi
interact
immun
system
provid
signific
inform
ration
antigen
design
anggraeni
et
al
mulder
et
al
encourag
recent
result
vlp
c
zhao
ao
yao
structur
biolog
emerg
power
tool
assist
ration
design
modern
hiv
vlp
vaccin
novel
protect
epitop
identifi
conform
epitop
map
studi
via
structur
biolog
liljeroo
et
al
malito
carfi
bottomley
addit
broad
potent
hiv
antibodi
discov
pool
antigenspecif
memori
b
cell
use
structur
biolog
highlight
novel
site
vulner
hiv
envelop
glycoprotein
epitop
j
huang
et
al
incorpor
vlp
antigen
strateg
modifi
insert
extend
epitop
membran
proxim
extern
region
mper
zhai
zhong
zariffard
spear
qiao
provid
better
display
conserv
bind
site
captur
broadli
neutral
antibodi
ingal
et
al
structur
biolog
equal
inform
vlp
engin
capsid
protein
form
vlp
need
correctli
fold
b
f
g
u
r
e
design
tool
vlp
vaccin
engin
multitud
tool
recent
advanc
synthet
biolog
enabl
screen
pathogenspecif
antigen
high
immunogen
potenti
engin
vlp
function
omic
technolog
enabl
rapid
identif
discoveri
novelpotenti
vaccin
antigen
structur
biolog
system
immunolog
assist
ration
reconfigur
engin
epitopesvlp
enhanc
immunogen
bioinformat
comput
biolog
acceler
data
analysi
translat
applic
knowledg
engin
vlp
function
differ
type
vlp
nonenvelop
vlp
commonli
engin
use
genet
engin
chemic
conjug
envelop
vlp
reli
pseudotyp
function
engin
b
vlp
engin
offer
broader
immunogen
improv
immunogen
enhanc
stabil
broadli
immunogen
vlp
obtain
display
multipl
antigen
distinct
epitop
pushko
et
al
schwartzman
et
al
highli
conserv
epitop
krammer
wiersma
et
al
comput
optim
epitop
carter
et
al
within
singl
vlp
improv
vlp
immunogen
achiev
incorpor
immunomodulatori
agent
dendrit
cell
target
antibodi
particl
structur
rosenth
et
al
vlp
stabil
enhanc
modul
particl
formul
collin
et
al
lua
et
al
system
immunolog
emerg
area
research
use
broad
integr
multilevel
approach
studi
immun
system
identifi
immun
correl
protect
immunogen
signatur
davi
tato
furman
combin
recent
technolog
advanc
human
immunolog
system
immunolog
provid
guidanc
ration
vaccin
design
system
immunolog
allow
assess
cell
type
immun
system
includ
special
b
white
blood
cell
state
function
signal
molecul
encod
gene
bird
accumul
data
captur
snapshot
human
immun
system
provid
valuabl
inform
creation
human
immun
respons
model
may
later
translat
improv
vaccin
design
davi
et
al
system
immunolog
approach
previous
undertaken
investig
immun
respons
live
attenu
yellow
fever
vaccin
hou
et
al
muyanja
et
al
follow
immun
comprehens
character
immun
system
perform
provid
insight
vaccin
mechan
action
similar
method
later
appli
malaria
vaccin
rt
systemslevel
approach
led
identif
molecular
cellular
signatur
associ
protect
immunogen
uniqu
vlpbase
vaccin
kazmin
et
al
system
immunolog
may
also
play
import
role
design
vaccin
capabl
stimul
part
immun
system
address
current
vaccin
davi
et
al
vlp
ideal
test
candid
system
immunolog
approach
due
abil
stimul
bcellmedi
immun
respons
well
prolif
respons
cytotox
lymphocyt
respons
gaus
et
al
correct
identif
epitop
stimul
immun
respons
crucial
design
novel
immunogen
epitop
region
within
antigen
recogn
band
tcell
receptor
patronov
doytchinova
potenti
band
tcell
epitop
map
use
bioinformat
comput
biolog
tool
howev
without
recent
improv
immunolog
character
method
identif
epitop
optim
stimul
human
immun
respons
becom
challen
bioinformat
comput
biolog
tool
potenti
acceler
data
analysi
translat
result
applic
knowledg
foster
discoveri
new
lead
antigen
reduc
number
empir
experi
xiang
vaccin
design
inher
complex
labori
process
softwar
algorithm
databas
outlin
potenti
streamlin
vaccin
develop
via
identif
candid
antigen
may
otherwis
overlook
epitop
map
essenti
design
vaccin
capabl
mount
robust
tand
bcell
respons
bioinformat
comput
biolog
also
assist
discoveri
conserv
epitop
sequenc
variabl
analysi
inraghavaantigendb
store
sequenc
structur
origin
epitop
pathogen
antigen
ansari
flower
raghava
comput
optim
broadli
reactiv
antigen
cobra
methodolog
recent
develop
overcom
challeng
associ
antigen
divers
influenza
subtyp
carter
et
al
silico
approach
use
consensu
build
gener
number
antigen
candid
term
cobra
antigen
use
identifi
ha
antigen
broadli
protect
vlp
divid
two
main
group
envelop
nonenvelop
envelop
vlp
selfassembl
capsid
acquir
lipid
layer
bud
host
cell
layer
absent
nonenvelop
vlp
mateu
insert
heterolog
antigen
otherwis
known
modular
nonenvelop
vlp
mainli
achiev
genet
fusion
chemic
conjug
peacey
wilson
baird
ward
size
insert
implic
vlp
assembl
correct
present
antigen
small
peptid
epitop
easili
insert
vlp
structur
without
affect
vlp
assembl
often
occur
modular
whole
larg
protein
domain
genet
fusion
popular
method
despit
timeconsum
errorpron
mateu
chemic
conjug
support
insert
larg
antigen
preform
vlp
modif
perform
natur
occur
conjug
site
use
chemic
crosslink
enzym
patel
swartz
tang
xuan
ye
huang
qian
downsid
chemic
conjug
incur
cost
requir
product
vlp
epitop
well
conduct
chemic
conjug
chackerian
smith
haw
bundi
recent
develop
technolog
start
address
cost
technolog
challeng
exampl
plug
display
system
technolog
base
two
protein
tag
catcher
react
irrevers
close
proxim
catcher
fuse
vlp
tag
fuse
vaccin
target
form
twocompon
vlp
vaccin
readi
use
brune
et
al
envelop
vlp
present
heterolog
membran
protein
ie
glycoprotein
nativ
configur
top
selfassembl
capsid
protein
without
need
engin
epitop
capsid
structur
process
call
pseudotyp
chua
et
al
kirchmeier
et
al
pseudotyp
one
alter
vlp
stabil
even
tropism
cronin
zhang
reiser
k
palomar
et
al
addit
transmembran
domain
within
foreign
viral
envelop
protein
replac
transmembran
domain
specif
virus
eg
vesicular
stomat
viru
improv
pseudotyp
effici
immunogen
kirchmeier
et
al
envelop
vlp
retroand
lentivlp
shown
promis
vaccin
candid
diseas
influenza
malaria
dengu
viru
chua
et
al
pitoiset
vazquez
bellier
engin
vlp
long
complex
process
often
unsuccess
insert
small
peptid
disrupt
vlp
structur
field
evolv
vlp
chimera
use
fundament
appli
research
mateu
murata
et
al
success
exampl
insert
larg
peptid
vlp
deriv
flock
hous
viru
engin
carri
receptor
domain
could
use
anthrax
antitoxin
well
vaccin
manayani
et
al
circul
virus
exhibit
high
antigen
variabl
high
mutat
rate
influenza
pose
substanti
challeng
current
vaccin
strategi
high
immunogen
desir
vaccin
attribut
potenti
translat
protect
target
infect
enhanc
immunogen
modular
antigen
must
strateg
insert
maxim
present
immun
system
previous
report
de
filett
et
al
hayn
et
al
howev
low
surfac
express
inabl
peptid
adopt
nativ
conform
result
weak
immunogen
insert
site
et
al
platform
base
upon
hbcag
papillomaviru
bovin
human
flock
hous
viru
fhv
other
thu
engin
take
advantag
surfaceexpos
loop
demonstr
enhanc
immunogen
murata
et
al
slupetzki
et
al
ye
et
al
peptid
insert
expos
loop
protrud
surfac
vlp
make
access
immun
system
short
peptid
display
rel
simpl
structur
pose
littl
problem
modular
within
expos
loop
yet
complex
structur
requir
platform
engin
anggraeni
et
al
incorpor
epitop
scaffold
expos
loop
vlp
display
whole
protein
domain
surfac
vlp
allow
present
multipl
antigen
epitop
increas
likelihood
epitop
adopt
nativ
conform
larg
size
howev
caus
steric
hindranc
result
compromis
vlp
assembl
lua
fan
chang
connor
middelberg
sever
strategi
develop
specif
modular
larg
antigen
long
flexibl
glycinerich
linker
engin
flank
antigen
loop
hbcag
platform
allow
spatial
separ
enabl
protein
insert
kratz
bottcher
nassal
though
effect
optim
linker
length
differ
antigen
need
empir
determin
steric
hindranc
also
address
case
reduc
antigen
content
surfac
vlp
exampl
peyret
et
al
engin
singl
polypeptid
compos
unmodifi
hbcag
fuse
chimer
hbcag
dual
express
construct
also
devis
coexpress
unmodifi
murin
polyomaviru
mupyv
antigenmodular
display
kda
rotaviru
antigen
tekew
fan
tan
middelberg
lua
although
method
lead
success
vlp
assembl
possibl
increas
antigen
mass
wherea
reduc
antigen
number
may
reflect
lower
immunogen
seen
charlton
hume
et
al
synthet
deriv
rt
malaria
vaccin
pitoiset
et
al
nevertheless
tradeoff
inevit
mass
antigen
increas
rel
carrier
necessit
understand
optim
domain
display
larg
antigen
report
use
novel
platform
base
upon
hpv
protein
acinetobact
phage
thrane
et
al
thrane
et
al
brune
et
al
mupyv
protein
led
develop
capsomer
platform
middelberg
et
al
schadlich
et
al
remov
carboxyl
termini
protein
yield
capsomer
incap
form
vlp
vivo
mupyv
capsomer
display
increas
stabil
although
less
immunogen
vlp
administ
adjuv
effect
middelberg
et
al
furthermor
quantit
process
studi
report
produc
e
coli
mupyv
capsomer
platform
capabl
produc
million
vaccin
dose
day
low
cost
highlight
suitabl
rapid
respons
lowcost
vaccin
platform
safe
robust
influenza
platform
illustr
aforement
broadli
immunoprotect
capabl
vlp
platform
multipl
subtyp
ha
antigen
display
either
individu
schwartzman
et
al
simultan
pushko
et
al
sequeira
et
al
tretyakova
pearc
flores
tumpey
pushko
base
vaccin
afford
protect
viru
challeng
multipl
speci
liu
massar
et
al
pyo
et
al
f
g
u
r
e
applic
synthet
biolog
vlp
vaccin
platform
enhanc
immunogen
peptid
achiev
insert
expos
loop
viral
capsid
protein
murata
et
al
slupetzki
et
al
ye
et
al
structur
properti
complex
peptid
maintain
incorpor
epitop
scaffold
expos
loop
schneemann
et
al
larg
antigen
modular
onto
vlp
vaccin
platform
use
long
flexibl
linker
maintain
structur
separ
viral
capsid
protein
antigen
kratz
et
al
onto
preform
vlp
use
plug
play
technolog
spycatcherspytag
brune
et
al
avitag
thrane
et
al
dual
express
modifi
unmodifi
viral
capsid
protein
reduc
steric
hindranc
permit
vlp
assembl
tekew
et
al
splitcor
system
permit
modular
antigen
extend
structur
coexpress
modifi
unmodifi
hbcag
core
fragment
walker
skamel
nassal
synthet
product
capsomer
minim
host
cell
contamin
reduc
requir
bioprocess
step
chuan
et
al
stabl
cell
line
adopt
strategi
proven
alreadi
success
product
multival
influenza
vlp
use
insect
high
five
cellbas
platform
sequeira
et
al
vaccin
product
scale
cost
puriti
vari
depend
vlp
purif
process
centrifug
depth
tangenti
flow
filtrat
use
initi
clarif
concentr
step
easili
scale
industri
level
chromatograph
method
use
remov
host
cell
dna
impur
densiti
gradient
ultracentrifug
easili
scalabl
anion
exchang
sec
timeconsum
costli
highlight
need
effici
costeffect
method
nonchromatograph
strategi
base
upon
aqueou
twophas
system
atp
process
present
use
enzym
product
industri
level
develop
vlp
purif
high
yield
rotaviru
vlp
purifi
insect
cell
supernat
use
atp
although
puriti
rel
poor
benavid
et
al
recent
singl
multistep
atp
use
purifi
human
parvoviruslik
particl
insect
cell
lysat
effio
et
al
puriti
level
greater
yet
appear
expens
yield
monolith
technolog
present
rapid
scalabl
method
offer
distinct
advantag
classic
packedb
chromatographi
vicent
et
al
hbsag
vlp
yeast
homogen
effect
purifi
use
hydroxyl
derivat
monolith
burden
jin
podgornik
bracewel
compar
densiti
gradient
centrifug
anionexchang
monolith
yield
gag
vlp
chines
hamster
ovari
cho
cell
supernat
steppert
et
al
sulfat
cellulos
membran
absorb
offer
signific
improv
convent
ion
exchang
membran
absorb
carvalho
fortuna
et
al
easili
scale
reduc
number
requir
process
step
may
qualifi
gener
purif
platform
vlpbase
vaccin
technol
carvalho
moleirinho
et
al
vlp
vaccin
platform
provid
opportun
overcom
sever
limit
tradit
vaccin
manufactur
substanti
variat
antigen
characterist
tradit
vaccin
infecti
natur
add
significantli
product
cost
demand
special
product
facil
tailor
manufactur
process
plotkin
robinson
cunningham
iqbal
larsen
standard
product
noninfecti
gener
vaccin
platform
use
display
variou
antigen
would
reduc
process
variat
ie
platform
remain
constant
provid
ground
establish
multiproduct
facil
streamlin
upstream
downstream
process
like
increas
effici
reduc
laboratori
wast
permit
cost
save
bulk
buy
equip
reagent
konstantinov
cooney
predict
bioprocess
may
allow
standard
facil
infrastructur
use
singleus
technolog
alreadi
use
vlp
vaccin
et
al
dispos
technolog
offer
sever
advantag
tradit
stainless
steel
equip
includ
lower
initi
invest
oper
cost
elimin
crosscontamin
flexibl
term
scale
lope
shukla
gottschalk
combin
dispos
technolog
vlp
platform
offer
advantag
multipl
level
would
facilit
vlp
translat
industri
increas
cost
regulatori
uncertainti
associ
produc
new
vaccin
long
challeng
vaccin
manufactur
ulmer
valley
rappuoli
intricaci
vaccin
manufactur
demand
substanti
amount
expert
contribut
significantli
cost
plotkin
et
al
expens
associ
vaccin
r
test
manufactur
well
poor
profit
margin
compar
current
drug
market
led
dramat
fall
fund
profitdriven
pharmaceut
compani
offit
howev
declin
thought
prematur
demonstr
throughout
review
vlp
technolog
advanc
rapidli
strong
focu
develop
platform
capabl
improv
vlp
product
yield
enabl
rapid
product
safer
cheaper
vaccin
particularli
combin
singleus
bioprocess
system
progress
set
continu
financi
invest
provid
notforprofit
sourc
nation
govern
intern
organ
philanthrop
bodi
particular
gavi
vaccin
allianc
balaji
bill
melinda
gate
foundat
wwwgatesfoundationorg
motiv
deliv
afford
vaccin
third
world
countri
world
biggest
vaccin
market
ensur
vaccin
puriti
safeti
efficaci
stabil
regulatori
author
govern
everi
stage
vaccin
manufactur
raw
materi
product
process
clinic
trial
beyond
includ
assess
certif
safe
viabl
manufactur
process
plotkin
et
al
meet
regulatori
requir
complic
process
particularli
manufactur
vaccin
oversea
market
util
newli
develop
bioprocess
streamlin
upstream
downstream
process
util
gener
vlp
base
vlp
platform
technolog
expect
reduc
regulatori
load
individu
vaccin
given
regul
base
purif
becom
well
character
vlp
platform
may
even
fast
track
vaccin
deliveri
respons
pandem
circumst
vaccinolog
experienc
impress
technolog
revolut
enabl
move
vaccin
develop
beyond
rule
pasteur
empir
approach
use
datarich
disciplin
system
biolog
immunolog
comput
biolog
assist
ration
vaccin
design
modern
approach
inde
last
decad
wit
trend
toward
use
altern
vaccin
design
attenu
pathogen
vlp
emerg
power
versatil
platform
product
today
vlp
use
vaccin
unmodifi
viral
assembl
parent
virus
also
scaffold
display
heterolog
antigen
addit
tremend
invest
made
develop
new
technolog
capabl
deciph
pathogen
biolog
vaccin
mechanist
respons
b
store
curat
extract
data
biolog
refer
databas
machin
learn
algorithm
use
inform
epitop
predict
structurebas
modular
design
complement
synthet
biolog
inform
provid
basi
engin
vlp
function
develop
gener
vlp
platform
offer
potenti
streamlin
bioprocess
parallel
infrastructur
predict
biosafeti
also
abil
manufactur
vaccin
unrel
virus
pathogen
sourc
ie
bacteria
parasit
protozoan
although
unabl
deliv
market
product
date
technolog
massiv
potenti
provid
near
futur
solut
untarget
infecti
agent
eg
antibioticresist
bacteria
hiv
malaria
tuberculosi
importantli
reduc
vaccin
develop
time
manufactur
cost
associ
current
vaccin
platform
author
acknowledg
support
australian
research
